Oncogenic Gene Dysregulation and Carcinogenesis

Cancer initiates from genetic alterations, including mutations, deletions and copy number gains, that function to activate cancer-promoting pathways or to block processes that normally inhibit cancer development. Through better understanding of pro- and anti-cancer signaling processes and how they become dysregulated in carcinogenesis and tumor progression, our team can improve biological tools for clinicians and devise molecularly targeted therapies to intervene.

The investigators in our department who focus on oncogenic gene dysregulation and carcinogenesis research are:

• Panagiotis Z. Anastasiadis, Ph.D.
• Esteban Braggio, Ph.D.
• John A. Copland III, Ph.D.
• Alan P. Fields, Ph.D.
• Baoan Ji, M.D., Ph.D.
• Verline Justilien, Ph.D.
• Rajappa S. Kenchappa, Ph.D.
• Georges Mer, Ph.D.
• Nicole R. Murray, Ph.D.
• Tushar C. Patel, M.B., Ch.B.